Reviews for Primary Care - Fall 2007 - (Page 10) Alpha Blockers for BPH Treatment continued 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. Caine M, Perlberg S, Meretyk S. A placebocontrolled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554. Kirby RS, Coppinger SWC, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: A placebo-controlled study. Br J Urol. 1987;60:136-142. Martorana G, Giberti C, Damonte P, et al. The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Med Sci. 1984;12:11-12. Lepor H, Auerbach S, Puras-Baez A, et al. A multicenter fixed-dose study of the safety and efficacy of terazosin in the treatment of the symptoms of benign prostatic hyperplasia. J Urol. 1992;148:1467-1474. Brawer MK, Adams G, Epstein H, et al. Terazosin in the treatment of benign prostatic hyperplasic. Arch Fam Med. 1993;2:929-935. Lloyd SN, Buckley JF, Chilton CP, et al. Terazosin in the treatment of benign prostatic hyperplasia: A multicentre, placebo-controlled trial. Br J Urol. 1992;70(Suppl 1):17-21. Terazosin [package insert]. North Chicago, IL: Abbott Laboratories; 2003. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154:105-109. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebocontrolled dose response multicenter study. J Urol. 1995;154:110-115. Doxazosin [package insert]. New York, NY: Pfizer Inc; 2003. Kirby RS. Terazosin in benign prostatic hyperplasia: effect on blood pressure in normotensive and hypertensive men. Br J Urol. 1998;82:373-379. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. Kirby RS. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology. 1995;46:182-186. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975. Kenny BA, Miller AM, Williamson IJ, et al. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996;118:871-878. Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 994;45:703-708. Lepor H for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892-900. Narayan P, Tewari A. The United States 93-01 Study Group: A second phase III multicenter placebo controlled study of 2 doses of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol. 1998;160: 1701-1706. Tamsulosin [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2003. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176(4):1529-1533. Wolters JP, Hellstrom WJ. Current concepts in ejaculatory dysfunction. Rev Urol. 2006;8 (4 supp):S18-S25. Alfuzosin [package insert]. Bridgewater, NJ: Sanofi-Synthelabo, Inc; 2004. 53. 54. 55. 56. 57. 58. 59. 60. Van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37:306-313. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia; a randomized, placebo-controlled trial. Urology. 2001;58:953-959. Roehrborn, CG, McConnell, JD, Barry, MJ and the AUA BPH Guideline Update Panel. Guideline on the management of benign prostatic hyperplasia (BPH). 2003; chapter 1-23. Available at: http://www.auanet.org/guidelines/bph.cfm. Accessed October 1, 2007. McNeill SA, Hargreave TB, Roehrborn CG, Members of the ALAUR Study Group. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urol. 2005;65:83-89. Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urol. 2007;69:805-809. Kaplan S, Fisch H, Berriman SJ, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome [abstract 1508]. J Urol. 2007;177(4 suppl):497-498. Kaplan S, Wilson TW. Association between BPH and the metabolic syndrome in the REDUCE population [abstract 1548]. J Urol. 2007;177 (4 suppl):511. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395-401. 10 VOL. 1 NO. 1 2007 REVIEWS FOR PRIMARY CARE http://www.auanet.org/guidelines/bph.cfm
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.